Vonoprazan

Vonoprazan
Skeletal formula of a vonoprazan molecule
Clinical data
Trade namesTakecab
ATC code
Pharmacokinetic data
BioavailabilityUnknown
Protein binding80%
MetabolismHepatic, by cytochrome P450 (3A4, 2B6, 2C19, 2D6)
Elimination half-life7.7 h
Duration of action> 24 h
ExcretionRenal
Identifiers
IUPAC name
  • 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine
CAS Number
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H16FN3O2S
Molar mass345.39 g·mol−1
3D model (JSmol)
SMILES
  • Fc1ccccc1-c2cc(CNC)cn2S(=O)(=O)c3cccnc3
InChI
  • InChI=InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
  • Key:BFDBKMOZYNOTPK-UHFFFAOYSA-N

Vonoprazan (trade name Takecab) is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.[1]

Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.[2]

References

  1. ↑ Garnock-Jones KP (2015). "Vonoprazan: first global approval". Drugs. 75 (4): 439–43. doi:10.1007/s40265-015-0368-z. PMID 25744862.
  2. ↑ Echizen H (2016). "The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations". Clin Pharmacokinet. 55 (4): 409–18. doi:10.1007/s40262-015-0326-7. PMID 26369775.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.